Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

Trial Profile

An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belzutifan (Primary)
  • Indications Haemangioblastoma; Neuroendocrine tumours; Pancreatic cancer; Renal cell carcinoma; Von Hippel-Lindau disease
  • Focus Registrational; Therapeutic Use
  • Acronyms LITESPARK-004
  • Sponsors Merck Sharp & Dohme Corp.; Peloton Therapeutics
  • Most Recent Events

    • 21 Oct 2023 According to a Merck & Co Media Release, additional applications are currently under regulatory agency review worldwide based on LITESPARK-004.
    • 06 Jun 2023 Results for the subgroup of patients with CNS HBs presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 18 Feb 2023 Results assessing Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan presented at the 2023 Genitourinary Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top